MKI67 and breast cancer: Nevertheless, in a meta-analysis, Chen et al. [58] analyzed 44 studies and concluded that high Ki-67 expression at diagnosis was associated with increased pCR rates in breast cancer patients treated with anthracycline- and/or taxane-containing NACs.